LCM
VRTX icon

Laurion Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurion Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,600
Closed -$308K – 1446
2018
Q3 		$308K Buy
+1,600
New +$285K ﹤0.01% 939

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Laurion Capital Management's VRTX Position: Q1 2026 in Review

Laurion Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 2,200 shares — an estimated $997K sold.

Laurion Capital Management first reported a position in VRTX in Q2 2015 and held it in 11 quarters. The position peaked at $28.3M in Q1 2017. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Laurion Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Laurion Capital Management sold 2,200 Vertex Pharmaceuticals shares in Q1 2026, an estimated $997K.
  • Laurion Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • Laurion Capital Management's Vertex Pharmaceuticals position peaked at $28.3M in Q1 2017.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.